| Authors: |
Nader-Marta G; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Zheng Y; Harvard Medical School, Boston, MA, USA.; Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Rosenberg SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Population Health Sciences, Weill Cornell Medicine, New York, NY, USA., Dibble KE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mayer EL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Poorvu PD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ruddy KJ; Medical Oncology, Mayo Clinic, Rochester, MN, USA., Guzman-Arocho YD; Harvard Medical School, Boston, MA, USA.; Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Collins LC; Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA., Peppercorn J; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Schapira L; Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA., Valenza C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Borges VF; Medical Oncology, University of Colorado Anschutz, Aurora, CO, USA., Tayob N; Harvard Medical School, Boston, MA, USA.; Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Come SE; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Warner E; Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Polyak K; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Winer EP; Yale University, Yale Cancer Center, New Haven, CT, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA. |
